3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Melanoma
34
Carcinoma, Non-Small-Cell Lung
22
Carcinoma, Renal Cell
20
Neoplasm Metastasis
13
Carcinoma, Hepatocellular
10
Brain Neoplasms
8
Lung Neoplasms
7
Skin Neoplasms
6
Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
5
Prostatic Neoplasms
5
Pancreatic Neoplasms
5
Kidney Neoplasms
5
Clear-cell metastatic renal cell carcinoma
5
Carcinoma, Transitional Cell
5
Uveal Melanoma
4
Ovarian Neoplasms
4
Myelodysplastic Syndromes
4
Multiple Myeloma
4
Glioblastoma
4
Carcinoma, Basal Cell
4
Carcinoma
4
Urinary Bladder Neoplasms
3
Urethral Neoplasms
3
Sarcoma
3
Recurrence
3
Mesothelioma
3
Liver Neoplasms
3
Leukemia, Myeloid, Acute
3
Histiocytoma, Malignant Fibrous
3
Interventions
pasireotide
1
lutetium Lu 177 dotatate
1
lanreotide
1
amino-acid, glucose, and electrolyte solution
1
Sunitinib
1
Octreotide
1
Everolimus
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
Ipilimumab
×
90 days
×
Clear all
No trials found.